New approaches to immunotoxicity testing. by Archer, D L
Environmental Health Perspectives
Vol. 43, pp. 109-113, 1982
New Approaches to
Immunotoxicity Testing
by Douglas L. Archer*
New approaches to immunotoxicity testing are reviewed and discussed. A method ofactivating
T-cells in vivo is presented which circumvents artifacts due to viability effects encountered with
in vitro mitogen assays. The use ofadoptive transfer approaches to combine the advantages ofin
vitro manipulation with in vivo function assays is discussed relative to natural killer cells. The
need for an in vitro metabolic activation step coupled to other in vitro immunologic assays is
discussed.
Introduction
Previous papers have demonstrated the impor-
tance of the immune system with regard to the
well-being of all animals. It has also been clearly
demonstrated that chemicals canmodifytheimmune
response, some for the benefit of the animal, e.g.,
immunopharmaceuticals, and some in potentially
harmful ways, e.g., chemical wastes and environ-
mental pollutants. Adequate coverage of the new
approachestoimmunotoxicitytestingwouldrequire
a separate symposium. The volume of new methods
being applied to all sorts ofimmunologic investiga-
tions is enormous, and the list ofliterature reports
increases monthly. Thousands of compounds and
their effects on the immune system require exami-
nation, and rapid, economical screening procedures
would certainly benefit industry as well as health
and regulatory agencies.
General Approaches to Testing
for Immunotoxicity
Table 1 shows the basic ways in which immune
response tests may be carried out. In the first
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category of tests the cells involved in a particular
immune response are exposed directly to the chem-
ical in vitro and the test for immune function is also
carried out in vitro. Although this approach is the
mosteconomical interms oftime and animals, ithas
some problems, most notably: metabolic alteration
of the compound may not be accounted for; distri-
bution of the -chemical into the immune compart-
ment is assumed; and cells are more susceptible to
damage in the relatively dilute in vitro microenvi-
ronment. A compromise approach in terms ofreal-
ism and economy calls for in vivo exposure to the
chemical followed by in vitro testing of immune
function of various lymphoid tissue. This is clearly
the most common approach currently used in im-
munotoxicity studies. The major advantages ofthis
approach are that distribution ofthe chemical to the
immune compartment is realistic and metabolism of
the compound may occur naturally. This approach
will be discussed further. Lastly, animals may be
exposed to the chemical in vivo and immune func-
tions tested in vivo. Although this is the most
Table 1. General immune response test scheme.
Toxicant exposure Test environment
In vitro In vitro
In vivo In vitro
In vivo In vivo
109realistic approach, it too has definite drawbacks:
large numbers of animals are usually required,
owing to the variability of immune responses even
in syngeneic populations of mice; and at present
many ofthe in vitro manipulations and tests cannot
be duplicated in vivo.
Returning to the in vivo exposure/in vitro analy-
sis scheme, some disadvantages with this approach
have recently been noted.
Lymphoproliferative Assays
Figure ladepictsthestandardlymphoproliferative
assay (or mitogen assay) as currently performed.
Although chemical contact occurs in vivo, it was
thought that preparation ofcells for in vitro culture
might remove the chemical; thus chemical and acti-
vator (or mitogen) might not be present simulta-
neously. Conversely, cells might be metabolically
or physically damaged by the chemical, making
them appear nonfunctional in the more hostile in
vitro situation, but compensatory mechanisms in
vivo might permit normal functions to occur. To
test these hypotheses, we used staphylococcal en-
terotoxin A (SEA), a T-cell specific mitogen (1)
with low toxicity to the mouse and with the added
advantage of a broad plateau of activation rather
a
a
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than the sharp dose-related peaks commonly seen
with the lectin mitogens concanavalin A or phyto-
haemmagglutinin (2). SEA was shown to be an in
vivo T-cell activator (3). The only in vitro culture
required was a4-hr period for3H-thymidine uptake
(Fig. lb). Thus, chemical and activator could be
present simultaneously in vivo. During these stud-
ies, we noticed that certain agents administered in
vivo, such as antithymocyte serum (ATS), which
disruptsT-cellmembraneintegrity, showedagreater
suppressive effect on in vitro mitogen responsive-
ness at far lower doses than were required to
suppress in vivo activation of T cells by SEA.
Table 2 shows the effects of ATS on in vitro
survival of cells, as determined by vital dye stain-
ing. Spleen cells from ATS-treated animals were
97-98% viable at the time ofharvest. Four hours of
culture had only a slight negative effect on in vitro
survival ofATS-treated cells. The rate ofcell death
of48-hr cultured cells (the routinely used LP assay
time) was greatly accelerated by ATS pretreat-
ment compared with the in vitro death rate of
controls. Magnification of the apparent damage in
theinvitroculture isadvantageousbecausegreater
sensitivity is attained; however, further work has
shown that realism may be compromised. Experi-
ments have indicated that the shorter the in vitro
STANDARD MITOGEN ASSAY
MITOGEN
A---- ADDED
O4ininIN VITRO-I
- TOXICANT CONTACTh--
IN VIVO ACTIVATION ASSAY
b
- -x
L.
110
O- ' IN Vivo
TOXICANT CONTACT -
FIGURE 1. (a) Standard lymphoproliferative assay. (b) In vivo activation assay (3).
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nTable 2. Viability ofATS-treated and untreated mouse spleen
cells after 4 and 48 hr in vitro.
Viability by trypan blue dye exclusion, %
Incubation time (mean ± SD)a
in vitro, hr Control for ATS ATS-treatedb
4 97± 1.1 95.2±1.5c
48 84 ± 5.1 50.7 ± 7.9c
an = 12 for each point
bTreatments carried out as described in text.
Cp < 0.01 by Student's t-test performed on arc-sines of
proportion of viability.
incubation time, the less the chance of amplified
effects on viability.
In Vitro Manipulation-
Adoptive Transfer
In a recent report concerning natural killer cells,
Kasai et al. (4) demonstrate how the concept of
short in vitro culture time might be applied. Natu-
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ral killer (NK) cells have become the focus ofmany
recentstudies onantitumoractivitiesoftheimmune
system because they appear to be one of the first-
linedefensesagainstvirus-orchemical-transformed
cells and have a functional counterpart in humans.
Kasai et al. attempted to demonstrate that cell
subpopulations which expressed NK activity in
vitro were actually responsible for NK activity in
vivo. The antitumorrole ofNK cells in vivo had not
yet been conclusively shown. The experimental
approachtakenbytheseinvestigatorsdemonstrates
how several new technologies could be applied to
immunotoxicologic investigations. Figure 2 depicts
the separation scheme used by Kasai et al. Their
procedure, which could be applied to chemical-
exposed animals as well, was as follows.
Spleen cells were removed from mice. Some cells
were placed in plastic dishes coated with antimouse
Fab antibody; in this way, immunoglobulin (Ig)-
bearing cells (B-cells) were enriched and non-Ig-
bearingcellswere removed. These populationswere
retained fortesting. Other spleen cells were passed
through a nylon wool column known to retain Ig-
bearingB-cells. Thus, T-cellsbearingThy 1 antigen
were enriched as were other non-Ig-bearing cells.
Some ofthese cells were treated with anti-Thy 1.2
antibody + C', to specifically lyse the mature, Thy
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FIGURE 2. Separation ofspleen cell populations used by Kasai
et al. (4).
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FIGURE 3. Adoptive transfer of tumor cells and separated
spleen cell subpopulations used by Kasai et al. (4).
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ITable 3. Ability of different lymphocyte sets to prevent lymphoma growth in vivo.
Tumor incidencea
Host = BALB/c, Host = A/J,
Spleen cell population Cell number (x 106) tumor = RLol tumor = YAC
A None -- 22/22 16/16
B Unselected 10 8/8 8/8
C Nylon-passed cells 5 14/15 15/15
D Thyl+ cells 5 8/8 8/8
E Ig+ cells 5 16/16 16/16
F Thyl- cells 5 19/22 22/22
G Thyl-Ig-Ly5+ cells 5 1/12 0/12
H Group G treated with anti-Ly5.1 + C 5 7/8 7/8
aResults of three individual experiments (4).
1-bearing T cells. Monoclonal antibody technology
currently assures the purity ofsuch antibody prep-
arations. The Thy 1- cells were found to have Ly 5
surface antigen by fluorescent antibody methods.
The Thy 1- Ly 5+ cells were coated with anti-Ly 5
antibody, but without complement because no lysis
was desired. The coated, viable cells were placed in
dishes with protein A-coated sheep erythrocytes.
Protein A specifically binds to the Fc portion of
antibody molecules; the Ly 5+ cells were bound to
erythrocytes by the protein A-antibody bridge and
could easily be separated from nonbound cells. The
erythrocytes were lysed by distilled H20 shock and
the Ly 5 + cells were freed and retained for testing.
These cells were 82-87% pure as determined by
fluorescence testingwith specific antisera. The total
in vitro time for these cell separations was rela-
tively short, probably less than 4 hr.
Figure 3 shows how the isolated cell populations
from each step ofseparation were mixed with RL1
or YAC tumor cells and adoptively transferred to
appropriate mice. The in vitro manipulated cells
were thus returned to an in vivo environment.
Table 3 depicts the results ofthe adoptive trans-
fer conditions. Spleen cells alone, although they
contained the NK cells, would not demonstrate
protection, probably because of insufficient num-
bers of NK cells. Not until the Ly 5+ Thy 1- cells
were highly enriched could protection be seen, but
then it was quite remarkable. Further, lysis ofthis
population by Ly 5 antisera showed that the popu-
lation carrying this surface antigen was definitely
involved in protection from the tumor. Such manip-
ulations are impossible in atotally in vivo situation.
By such separations, NK cells or other desired
populations could be isolated in vitro, exposed to
chemical treatment to assess direct effects, particu-
larly ifin vitro metabolic activation could be carried
out, and returned to the natural in vivo environ-
ment in a syngeneic host fortesting. Likewise, such
tests could be done on cells fromchemical-pretreated
animals.
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Combining in vitro manipulation with adoptive
transfer and in vivo functional analysis is one way
in which immunotoxicologic studies might be car-
ried out using currently available methodology and
averting possible erroneous conclusions caused by
problems associated with in vitro survivability.
New Approaches to Screening
for Immunotoxicants
Recently, Kutz et al. (5) have applied the Mishell-
Dutton in vitro antibody-forming cell system to
screening a large number of environmentally rele-
vant compounds. Many of these chemicals were
showntobeimmunosuppressivebutdirectlycytotoxic
to lymphoid cells in vitro at suppressive levels
(Table 4). These chemicals included the organotins,
several heavy metals and polychlorinated biphe-
nyls. Others, shown in Table 5, were suppressive
but not cytotoxic. Most notably, azathioprene was
suppressive in vitro at levels easily attained in vivo
Table 4. Effects of various chemicals on the direct PFC
response and viability of Mishell-Dutton cultures.
90% PFCSD, 50% VRD,
,ug/culture ,ug/culture
Compound (mean ± SD)a (mean ± SD)a
Cytotoxic
DBTC 0.092 ± 0.003 0.06 ± 0.01
DPTC 0.46 ± 0.006 0.27 ± 0.06
DOTC 3.80 ± 0.15 1.18 ± 0.05
DETC 4.77 ± 0.16 3.72 ± 0.06
DMTC 5.21 + 0.35 3.53 ± 0.03
Propyl gallate 8.95 ± 0.13 5.08 ± 0.36
Mercuric chloride 8.77 ± 0.35 8.11 ± 1.14
Cadmium chloride 8.90 ± 0.24 9.43 ± 0.42
Aroclor 1254 17.25 ± 1.60 17.92 ± 0.40
Aroclor 1248 19.02 ± 0.33 17.72 ± 0.19
Nickel chloride 45.42 ± 0.09 37.93 ± 0.80
'90% PFCSD = 90% plaque-forming cell suppressive dose
compared to nontreated positive controls; 50% VRD = 50%
viability reducing dose. Data are expressed as means + stan-
dard deviations of triplicate cultures (5).
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response and viability of Mishell-Dutton cultures.
90% PFCSD, 50% VRD,
jig/culture ,ug/culture
Compound (mean t SD)Y (mean ± SD)Y
Immunosuppressive
(at noncytotoxic doses)
Azathioprine
(Imuran) 0.51 t 0.19 16.39 ± 0.52
Gallic acid 7.56 + 0.07 < 300
Methyl paraben 98.90 t 0.95 265.36 ± 11.08
Dextran sulfate 101.17 t 5.85 < 300
Vanillin 199.75 t 6.64 < 300
No detectable effect
Chromic chloride < 300 < 300
Cyclophosphamide < 300 < 300
Lead chloride < 300 < 300
Sodium chloride < 300 < 300
(182 ,ug Cl)
and with similar suppression kinetics. Thus, some
degree of predictability was achieved with this
system. Cyclophosphamide also had no effect on
this system, owing to the lack of the required
microsomal activation ofthis chemical. The need for
an in vitro activation step in this potentially useful
procedure is discussed by Tucker (6). Vos (7) and
Boonnan (8) alsoreport onnewmethods forassessing
the effects ofchemicals onthe adultimmune system
and the developing immune system, respectively.
Conclusion
Immunology as related to toxicology is an excit-
ing field of research. We are currently learning
which methods are applicable to toxicity testing
and improving and adapting others to make them
suitable. While no one magic test will suffice, itmay
be possible in the very near future to report the
development of more rapid, reliable, economical
screening methods for a wide range of immune
functions which have predictive value to the whole
animal.
REFERENCES
1. Smith, B. G., andJohnson, H. M. The effect ofstaphylococcal
enterotoxins on the primary in vitro immune response. J.
Immunol. 115: 575-578 (1975).
2. Archer, D. L., Smith, B. G., Ulrich, J. T., and Johnson, H.
M. Immune interferon induction by T-cell mitogens involves
different T-cell subpopulations. Cell. Immunol. 48: 420-426
(1979).
3. Archer, D. L., Smith, B. G., and Peeler, J. T. Activation of
murine T-lymphocyte DNA synthesis in vivo by staphylococ-
cal enterotoxin A: Applicability to immunotoxicity testing.
IRCS Med. Sci. 8: 457 (1980).
4. Kasai, M., Leclerc, J. C., McVay-Boudreau, L., Shen, F. W.,
and Cantor, H. Direct evidence that natural killer cells in
nonimmune spleen cell populations prevent tumor growth in
vivo. J. Exptl. Med. 149: 1260-1264 (1979).
5. Kutz, S. A., Hinsdill, R. D., and Weltman, D. J. Evaluation
of chemicals for immunomodulatory effects using an in vitro
antibody-producing assay. Environ. Res. 22: 368-378 (1980).
6. Tucker, A. N., Sanders, V. M., Hallett, P., Kauffmann, B.,
and Munson, A. E. In vitro immunotoxicological assays for
detection ofcompounds requiring metabolic activation. Envi-
ron. Health Perspect. 43: 123-127 (1982).
7. Vos, J. G., Krajnc, E. I., and Beekhof, P. Use of the
enzyme-linked immunosorbent assay (ELISA) in immuno-
toxicity testing. Environ. Health Perspect. 43: 115-121 (1982).
8. Boorman, G. A., Luster, M. I., Dean, J. H., and Campbell,
M. L. Assessment ofmyelotoxicity caused by environmental
chemicals. Environ. Health Perspect. 43: 129-135 (1982).
February 1982 113